News
BEIGF
23.75
NaN%
--
Tracking Baker Brothers' Portfolio: Q2 2026 Update
Seeking Alpha · 5d ago
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Seeking Alpha · 08/10 23:22
Tracking Baker Brothers Portfolio: Q1 2026 Update
Seeking Alpha · 07/21 17:26
I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)
Seeking Alpha · 07/16 19:53
Baird International And Global Growth Funds Q2 2026 Contributors And Detractors
Seeking Alpha · 07/13 19:33
Amgen: Time For An Upgrade? Yes, I Think So
Seeking Alpha · 06/05 12:00
BeOne projects 2026 revenue of $6.3B-$6.5B as it raises guidance by $100M
Seeking Alpha · 05/06 17:34
Johnson & Johnson: Why I See Downside Ahead
Seeking Alpha · 04/17 14:42
Tracking Baker Brothers Portfolio - Q4 2025 Update
Seeking Alpha · 03/18 00:54
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 12/16/2025 14:19
Zymeworks shifts to a royalty-driven business model
Seeking Alpha · 11/18/2025 17:24
Jazz, Zymeworks’ Ziihera trial shows significant PFS improvement, shares rally
Seeking Alpha · 11/17/2025 12:13
Saudi sovereign wealth fund cuts holdings of U.S. stocks
Seeking Alpha · 11/16/2025 14:16
BeOne Medicines outlines $5.1B–$5.3B 2025 revenue target amid BRUKINSA momentum and expanding pipeline
Seeking Alpha · 11/06/2025 20:17
BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline
Seeking Alpha · 10/14/2025 20:24
BeOne Medicines' sonrotoclax gets FDA breakthrough therapy status
Seeking Alpha · 10/13/2025 13:08
More
Webull provides a variety of real-time BEIGF stock news. You can receive the latest news about Beigene through multiple platforms. This information may help you make smarter investment decisions.
About BEIGF
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.